Market Closed -
Nasdaq
21:00:00 25/06/2024 BST
|
5-day change
|
1st Jan Change
|
0.64
USD
|
+0.30%
|
|
-9.37%
|
-20.99%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
310.7
|
322.4
|
69.8
|
44.32
|
80.15
|
63.33
|
-
|
-
|
Enterprise Value (EV)
1 |
310.7
|
322.4
|
8.894
|
-65.66
|
80.15
|
-25.67
|
63.33
|
63.33
|
P/E ratio
|
-5.07
x
|
-6.56
x
|
-1.01
x
|
-0.82
x
|
-0.94
x
|
-1.92
x
|
-0.99
x
|
-0.91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
26
x
|
16.5
x
|
3.78
x
|
3.11
x
|
3.98
x
|
1.18
x
|
6.43
x
|
10.9
x
|
EV / Revenue
|
26
x
|
16.5
x
|
0.48
x
|
-4.61
x
|
3.98
x
|
-0.48
x
|
6.43
x
|
10.9
x
|
EV / EBITDA
|
-6,259,736
x
|
-6,561,357
x
|
-115,458
x
|
944,064
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-7,106,010
x
|
-7,729,376
x
|
-113,162
x
|
1,965,120
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
1.85
x
|
-
|
0.71
x
|
0.52
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
25,408
|
29,071
|
29,959
|
54,717
|
98,950
|
98,950
|
-
|
-
|
Reference price
2 |
12.23
|
11.09
|
2.330
|
0.8100
|
0.8100
|
0.6400
|
0.6400
|
0.6400
|
Announcement Date
|
19/03/20
|
18/03/21
|
24/03/22
|
15/03/23
|
22/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
11.94
|
19.58
|
18.45
|
14.25
|
20.13
|
53.82
|
9.85
|
5.833
|
EBITDA
|
-49.64
|
-49.14
|
-77.03
|
-69.55
|
-
|
-
|
-
|
-
|
EBIT
1 |
-51.08
|
-53.28
|
-81.67
|
-73.16
|
-97.69
|
-41.62
|
-111.1
|
-136.7
|
Operating Margin
|
-427.78%
|
-272.08%
|
-442.73%
|
-513.4%
|
-485.34%
|
-77.33%
|
-1,127.9%
|
-2,343.18%
|
Earnings before Tax (EBT)
1 |
-
|
-44.08
|
-75.66
|
-64.68
|
-81.21
|
-50.48
|
-115.3
|
-113
|
Net income
1 |
-43.04
|
-44.08
|
-75.66
|
-64.92
|
-81.58
|
-47.56
|
-103.8
|
-131.4
|
Net margin
|
-360.38%
|
-225.09%
|
-410.15%
|
-455.58%
|
-405.29%
|
-88.37%
|
-1,053.33%
|
-2,252.62%
|
EPS
2 |
-2.410
|
-1.690
|
-2.300
|
-0.9900
|
-0.8600
|
-0.3333
|
-0.6433
|
-0.7000
|
Free Cash Flow
|
-43.73
|
-41.71
|
-78.6
|
-33.41
|
-
|
-
|
-
|
-
|
FCF margin
|
-366.19%
|
-212.98%
|
-426.05%
|
-234.5%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
18/03/21
|
24/03/22
|
15/03/23
|
22/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.895
|
1.445
|
2.746
|
2.23
|
7.828
|
3.176
|
2.679
|
6.867
|
7.407
|
36.6
|
7.091
|
4.816
|
5.31
|
-
|
-
|
EBITDA
|
-20.82
|
-
|
-
|
-
|
-12.68
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-22.05
|
-20.15
|
-18.43
|
-20.99
|
-13.59
|
-22.66
|
-21.47
|
-22.67
|
-30.9
|
11.11
|
-13.99
|
-19.43
|
-19.94
|
-
|
-
|
Operating Margin
|
-566.03%
|
-1,394.26%
|
-671.05%
|
-941.39%
|
-173.58%
|
-713.38%
|
-801.49%
|
-330.13%
|
-417.11%
|
30.35%
|
-197.32%
|
-403.37%
|
-375.53%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.24
|
-17.97
|
-16.36
|
-18.28
|
-12.08
|
-19.68
|
-18.02
|
-19.07
|
-24.65
|
14.38
|
-18.07
|
-23.32
|
-23.46
|
-
|
-
|
Net income
1 |
-21.24
|
-17.97
|
-16.36
|
-18.28
|
-12.31
|
-19.68
|
-18.02
|
-19.07
|
-24.82
|
14.38
|
-18.34
|
-20.61
|
-21.88
|
-
|
-
|
Net margin
|
-545.19%
|
-1,243.46%
|
-595.63%
|
-819.73%
|
-157.27%
|
-619.65%
|
-672.49%
|
-277.65%
|
-335.06%
|
39.3%
|
-258.58%
|
-428.02%
|
-412.08%
|
-
|
-
|
EPS
2 |
-0.6400
|
-0.4000
|
-0.2300
|
-0.2500
|
-0.1600
|
-0.2700
|
-0.2200
|
-0.1700
|
-0.2200
|
0.1100
|
-0.1433
|
-0.1500
|
-0.1467
|
-0.1800
|
-0.1900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/22
|
16/05/22
|
11/08/22
|
14/11/22
|
15/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
22/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
60.9
|
110
|
-
|
89
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-43.7
|
-41.7
|
-78.6
|
-33.4
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-36.5%
|
-32.2%
|
-61.6%
|
-67.6%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-29.9%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
143.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
6.600
|
-
|
3.270
|
1.560
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.340
|
-1.510
|
-2.010
|
-0.3100
|
-
|
-
|
-
|
-
|
Capex
|
2
|
2.37
|
12.6
|
5.02
|
-
|
-
|
-
|
-
|
Capex / Sales
|
16.74%
|
12.11%
|
68.2%
|
35.21%
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
18/03/21
|
24/03/22
|
15/03/23
|
22/03/24
|
-
|
-
|
-
|
Last Close Price
0.64
USD Average target price
4.8
USD Spread / Average Target +650.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.99% | 63.33M | | +55.19% | 815B | | +46.60% | 654B | | -6.09% | 354B | | +21.92% | 337B | | +19.00% | 247B | | +3.84% | 229B | | +13.83% | 219B | | +10.86% | 171B | | -2.78% | 159B |
Other Pharmaceuticals
|